Concepedia

Wanxing Chai‐Ho

WC

Statistics

Publications

11

Citations

1K

H-Index

11

Active since

2021

Affiliations

University of California, Los Angeles(Current)

The University of Texas MD Anderson Cancer Center

Moffitt Cancer Center

University of California San Diego

City Of Hope National Medical Center

Wanxing Chai‐Ho is an author at University of California, Los Angeles specializing in cancer immunotherapy, medicine, and oncology.

Publications per year

2021–2025

11

Publications

11

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Corey Cutler, Stephanie J. Lee, Sally Arai et al. · Blood · 2021 · 327 citations · Full text

Life Sciences, Immunology, Surgery +9

Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

Assuntina G. Sacco, Ruifeng Chen, Francis P. Worden et al. · The Lancet Oncology · 2021 · 258 citations · Full text

Medicine, Oncology, Cancer Pharmacology +10

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022

Peter L. Greenberg, Richard M. Stone, Aref Al‐Kali et al. · Journal of the National Comprehensive Cancer Network · 2022 · 125 citations · Full text

Medicine, Hematology, Oncology +17

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results

Naval Daver, Paresh Vyas, Suman Kambhampati et al. · Journal of Clinical Oncology · 2023 · 121 citations · Full text

Medicine, Immunology, Pharmacology +17

AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results

David A. Sallman, Adam Asch, Suman Kambhampati et al. · Clinical Lymphoma Myeloma & Leukemia · 2021 · 51 citations

Medicine, Oncology, Pharmacology +10

1–5 of 11